

PCT LTD enters into Manufacturers Representative Agreement for Sales of Annihilyzer® Infection Control Systems in the Ohio Valley Region.

LITTLE RIVER, SC February 7, 2019--- PCT LTD (OTC Pink: PCTL), through its operating subsidiary, Paradigm Convergence Technologies Corporation (PCT Corp), a leader in environmentally safe, non-toxic, antimicrobial solutions for infection control, announced today it has entered into a Manufacturer's Representative Agreement with DTS of Cleveland, OH (DTS), for the sale of Annihilyzer® Infection Control Systems in Ohio, West Virginia, Western Pennsylvania, Michigan, Indiana and Kentucky.

Nick Giarelli, CEO at DTS, "DTS is very excited to be working with PCT Health as a Manufacture Representative for the Ohio Valley Region of the US. DTS and its parent company Wave Imaging have many years of experience selling capital equipment to hospitals and clinics throughout the region and will be able to use its client database to bring PCT's Annihilyzer Infection Control System into the facilities at a faster pace due to its strong reputation for sales and long-term support."

Jody Read, CEO of PCT LTD, "We are excited to establish this relationship with such a trusted partner in the area. Nick and his team will allow PCT to accelerate growth and deployment of systems throughout the region and we are confident in their ability to serve our customers."

PCT's Annihilyzer® Infection Control System is capable of onsite production of a non-harmful, Green Seal Certified tuberculocidal disinfectant that is effective against 99.9999% of organisms such as Clostridium difficile (C. diff.), MRSA, VRE, CRE, Klebsiella pneumoniae, and Pseudomonas. The Company's primary disinfecting fluid solution is effective against common healthcare pathogens such as Tuberculosis (TB), HIV-1, Hepatitis C, Norovirus, Rhinovirus, Influenza A, H1N1, Candida albicans, and more; food processing bacteria including E. coli, Listeria, and Salmonella; and organisms of veterinarian concern such as parvovirus, distemper and Bordetella. This group was very excited about the ability to reduce Hospital Associated Infections (HAI) using a non-synthetic solution which is not harmful to patients, staff, equipment, or furniture. The ability to track the fluid's efficacy and provide cleaning and disinfecting protocols will reduce human error and increase the effectiveness of infection prevention and disinfection programs.

The RFID fluid tracking system can be customized to track housekeeping employees to ensure that all proper cleaning and disinfecting protocols are being performed during the cleaning process. This in turn assists the hospital administration by supplying valuable data regarding who, what, when and how all areas of the hospital were cleaned and disinfected.

This system also incorporates the use of Electrostatic Smart Applicators that apply positively charged disinfectant to all surfaces. Human error associated with improper application and coverage of disinfectant is no longer an issue as the electrostatic applicators ensure that all surfaces are covered and wrapped with disinfectant. Fogging or misting systems are not time or cost effective whereas the electrostatic application process takes less time, so room turnover is much faster.

About PCT LTD

PCT LTD ("PCTL") focuses its business on acquiring, developing and providing sustainable, environmentally safe disinfecting and tracking technologies products. The company acquires and holds rights to innovative products and technologies, which are commercialized through its wholly-owned operating subsidiary, Paradigm Convergence Technologies Corporation (PCT Corp). Currently trading on OTC, "PCTL" aspires to and is actively engaged in preparations for up-listing its common stock to a

national securities exchange. The Company established entry into its target markets with commercially-viable products and now prepares to gain market share.

PCT Corp's business mission is to profitably provide state-of-the-art Electro-Chemical Activation equipment, disinfecting fluid solutions and PCT Corp's patented tracking system to hospitals and other facilities for the documentable remediation of Hospital Acquired Infections (HAI's) from organisms such as *Clostridium difficile* (C. diff.), MRSA, VRE, CRE, *Klebsiella pneumoniae*, and *Pseudomonas*, as well as to sell ECA fluid solutions to agricultural markets for the remediation, control and suppression of microbial contamination and disease of certain commercial crops. The Company's primary fluid solution, branded Hydrolyte®, is an EPA registered "hospital-level" disinfectant effective against common healthcare pathogens such as Tuberculosis (TB), HIV-1, Hepatitis C, Norovirus, Rhinovirus, Influenza A, *Candida albicans*, and more; food processing bacteria including *E. coli*, *Listeria*, and *Salmonella*; and organisms of veterinarian concern such as parvovirus, distemper and *Bordetella*. PCT Corp.'s proprietary equipment product line includes: 1) PCT Hydrolyte® Generators, 2) PCT Annihilyzer® Infection Control Systems, and 3) SurvivaLyte® equipment. The Hydrolyte® Generators produce large volumes of electrolyzed water for the agriculture, oil and gas, and fluid distribution markets. The Annihilyzer® Infection Control Systems, which boast patented RFID material tracking technology, Electrostatic Smart Applicators, on-site automated ECA generators, and Green Seal standards containing stringent performance, health, and sustainability criteria, are ideal for hospitals and healthcare facilities. The SurvivaLyte® unit is a portable, small volume generator with applications such as disaster recovery, emergency preparedness, remote on-site needs, farm and ranch, and personal use. PCT Corp's unique patented systems and human-safe products provide next-generation cleaning, sanitizing, disinfecting and decontaminating fluid solutions to the ever-present problems of microbial infection and infestation.

Forward-Looking Statements

This press release contains "forward-looking statements" as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21B of the Securities Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact and may be "forward-looking statements."

Such statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Such statements involve risks and uncertainties, including but not limited to: any implied or perceived benefits resulting from the continued positive results relating to the installation of PCT's Annihilyzer® systems in hospitals; the results of any manufacturers' representative and/or license agreements, actual sales revenue to be derived from agreements; PCT LTD's and its subsidiary's business prospects; PCT LTD's ability to raise sufficient funds to satisfy its working capital requirements; the ability of PCT LTD to execute its business plan or list its common stock on a national stock exchange; benefits of the Annihilyzer® Infection Control Systems, Hydrolyte® generators and fluids; any other effects resulting from the information disclosed above; risks and effects of legal and administrative proceedings and government regulation; future financial and operational results; competition; general economic conditions; and the ability to manage and continue growth. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual outcomes may vary materially from those indicated.

Important factors that could cause actual results to differ materially from the forward-looking statements PCT LTD makes in this press release include market conditions and those set forth in reports or documents it files from time to time with the United States Securities Exchange Commission. PCT LTD undertakes no obligation to revise or update such statements to reflect current events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

Contact:

Gary Grieco, Chairman of the Board

(843) 390-7900 Office

(843) 390-2347 Fax

www.para-con.com

www.pcthealth.com

Brokers and Analysts:

Chesapeake Group

(410)825-3930

info@chesapeakegp.com